CTOs on the Move

Liquidia Technologies

www.liquidia.com

 
Liquidia Technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.liquidia.com
  • PO Box 110085
    Research Triangle Park, NC USA 27709
  • Phone: 919.328.4400

Executives

Name Title Contact Details

Funding

Liquidia Technologies raised $22.4M on 12/26/2019

Similar Companies

Exscientia

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We`ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

International Drug Development Institute

International Drug Development Institute is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nanosphere

Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. Headquartered in Northbrook, Illinois, Nanosphere was founded in 1999 based upon technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public (NASDAQ: NSPH), and has remained committed to continued scientific discovery and innovation with more than 175 patents to its name.

Prolong Pharmaceuticals

Prolong is dedicated to the global biotechnology market, and to developing relationships with companies worldwide for raw material supply, commercial development and marketing of its new wave of products - the Supergenerics.

BillionToOne

BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible. Our proprietary molecular counting platform can accurately count DNA molecules at the single-count level to help improve disease detection.